In summary, we have taken a step toward establishing the inhibition of the NCS-1/Ric8a complex as a treatment for FXS or other neurodevelopmental disorders associated with synaptic homeostasis dysfunction. This evidence concerns the gene NCS1 and fragile X syndrome.